The win comes shortly after the Swiss-based company shared positive early results for its radiotracer during this week’s Alzheimer’s Association International Conference.

Normal scores on thinking and memory tests at the start of a 14-year-long study were associated with fewer problems later in life, regardless of amyloid brain plaques.

Blue Earth Diagnostics announced Tuesday that it has administered its new radiohybrid imaging agent to patients taking part in a clinical trial for prostate cancer.

In addition to his dedication to early cancer detection, the renowned 57-year-old physician developed a number of FDG PET algorithms used for managing cancer patients, including decision models for the Centers for Medicare and Medicaid Services.

Memorial Sloan Kettering Cancer Center researchers described their findings as a "potent" first step forward in using oncology-based approaches to combat the virus.

At least a dozen trials across the globe are underway testing LDRT as a treatment for virus-related pneumonia, but some experts aren't convinced.

A team of international researchers queried 35 countries representing nearly 75% of all global nuclear medicine sites, publishing their findings in the Journal of Nuclear Medicine.

The society announced a new president and president-elect to lead its member technologists during its virtual meeting.

Beijing researchers tested the radiopharmaceutical—64Cu-EBRGD—in a handful of patients, with no adverse symptoms up to a week after their exam.

One Stanford University School of Medicine radiologist is hopeful this will lay the groundwork for an entirely new subspecialty in nuclear medicine and radiology.

The organization also announced its incoming president-elect and vice president-elect.

18F-PI-2620 revealed the "first evidence" that the radiopharmaceutical could help reliably detect progressive supranuclear palsy, experts said in JAMA Neurology.